Evidence map›Paper›PMID 41989307›Full record

ArticleJournal of virology2026

HuR enhances SARS-CoV-2 non-structural protein translation through the genomic 5'-UTR, by promoting polypyrimidine tract-binding protein binding.

Harsha Raheja, Risabh Sahu, Trinath Ghosh, Santu Paul, Priya Rani, Ashish Aneja, Biju George, Oyahida Khatun, Shashank Tripathi, Saumitra Das

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Harsha Raheja *Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.ORCID 0000-0003-1695-7512
Risabh Sahu *Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.ORCID 0009-0004-1027-1258
Trinath GhoshNational Institute of Biomedical Genomics, Kalyani, West Bengal, India.
Santu PaulDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
Priya RaniDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
Ashish AnejaDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
Biju GeorgeDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
Oyahida KhatunDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.
Shashank TripathiDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.ORCID 0000-0002-5702-9248
Saumitra DasDepartment of Microbiology and Cell Biology, Indian Institute of Science, Bangalore, India.ORCID 0000-0002-0640-3586

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral RNA associates with different RNA-binding host proteins at each stage of its life cycle. We found sequence-dependent binding of one such important protein, human antigen R (HuR), to the SARS-CoV-2 5'-UTR and studied its potential role in the viral life cycle. The knockdown and knockout studies revealed the importance of such binding in viral translation. We identified 5'-UTR mutations in SARS-CoV-2 variants of concern that altered the HuR-binding affinity. Interestingly, HuR enhanced non-structural protein translation through the genomic 5'-UTR by promoting polypyrimidine tract-binding protein binding to the 5'-UTR. HuR knockout increased the sensitivity to remdesivir treatment by decreasing its half-maximal inhibitory concentration. An antisense oligonucleotide (whose binding site overlapped the HuR-binding site) reduced viral RNA levels in wild-type cells but not HuR-knockout cells. Our results indicate that HuR regulates the balance between SARS-CoV-2 structural and non-structural proteins and guides the infection of viral variants, implying that HuR can potentially be explored as an antiviral target.IMPORTANCEViruses interact with various host proteins throughout their life cycle. A key protein is HuR, an RNA-binding protein regulating RNA stability and translation. HuR binds to viral RNAs at the 5'-UTR or 3'-UTR, influencing translation and replication. We identified conserved HuR binding sites in the SARS-CoV-2 5'-UTR across beta coronaviruses. This binding enhances translation initiation from the genomic 5'-UTR, increasing non-structural protein production essential for replication. Additionally, we discovered that another host protein, PTB, is recruited by HuR to the viral 5'-UTR, aiding ribosome loading. This regulation shows that the virus exploits HuR for its benefit. Targeting HuR may help control the SARS-CoV-2 life cycle. HuR knockout increased sensitivity to remdesivir, an antiviral drug. Using an antisense oligonucleotide to block HuR binding effectively reduced viral RNA levels. Our findings highlight HuR's critical role in viral protein production regulation and its potential as a therapeutic target against SARS-CoV-2.

Indexed as

5' Untranslated RegionsELAV-Like Protein 1Polypyrimidine Tract-Binding ProteinProtein BiosynthesisSARS-CoV-2Viral Nonstructural ProteinsAdenosine MonophosphateAlanineAnimalsAntiviral AgentsBinding SitesCOVID-19Genome, ViralHEK293 CellsHumansProtein Binding5' Untranslated RegionsAdenosine MonophosphateAlanineAntiviral AgentsELAVL1 protein, humanELAV-Like Protein 1Polypyrimidine Tract-Binding ProteinremdesivirRNA, ViralViral Nonstructural Proteins5′-untranslated regiongenomic RNAhuman antigen Rsevere acute respiratory syndrome coronavirus 2translation

Identifiers

PMID41989307
PMCPMC13185593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.